# Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fed Condition

> **NCT01589562** · PHASE1 · COMPLETED · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 28 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Megace 800mg/20ml
- **DRUG:** DW-ES(B) 625mg/5ml

## Key facts

- **NCT ID:** NCT01589562
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2013-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01589562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01589562, "Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fed Condition". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01589562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*